https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)2011-06-04 00:00:002011-06-04 00:00:00Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-4032011-06-03 00:00:002019-02-15 08:40:03Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-01 / J. Immunother. 2011 Jun;34(5):409-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-01 / J. Immunother. 2011 Jun;34(5):409-182011-06-01 00:00:002019-02-15 08:36:02PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-01 / Clin. Cancer Res. 2011 Jul;17(14):4705-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-01 / Clin. Cancer Res. 2011 Jul;17(14):4705-182011-06-01 00:00:002019-02-15 08:46:41Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-01 / Front Biosci (Schol Ed) 2011 Jun;3:1486-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-01 / Front Biosci (Schol Ed) 2011 Jun;3:1486-992011-06-01 00:00:002019-02-15 08:50:08Cancer stem cells: perspectives of new therapeutical approaches for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-30 / Horm. Metab. Res. 2011 Nov;43(12):877-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-30 / Horm. Metab. Res. 2011 Nov;43(12):877-832011-05-30 00:00:002019-02-15 09:22:49Oncolytic viruses for the treatment of neuroendocrine tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-612011-05-24 00:00:002019-02-15 08:53:07Immunotherapy for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-12 / Cell. Immunol. 2011;270(2):188-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-12 / Cell. Immunol. 2011;270(2):188-972011-05-12 00:00:002019-02-15 08:40:05Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-672011-05-10 00:00:002019-02-15 08:52:51Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-5042011-05-09 00:00:002021-11-15 16:58:35Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
